https://www.selleckchem.com/pr....oducts/fosbretabulin
2) and superior to that of Younger-S group (176.5). Incidence of adverse reactions in Older-S group (47.0%) was similar to that of Older-C group (44.8%), or Younger-S group (49.8%). This study showed good safety and immunogenicity of Sinovac EV71 vaccine in children aged 36-71 months. NCT03909074. https//clinicaltrials.gov/ct2/show/NCT03909074?term=NCT03909074draw=2rank=1. https//clinicaltrials.gov/ct2/show/NCT03909074?term=NCT03909074draw=2rank=1.Sch
Like
Comment
Share
